Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


13.07.2020

1 Cancer Res
2 Gynecol Oncol
1 Int J Cancer
1 Lancet Oncol
1 Oncogene
1 Oncology (Williston Park)
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Cancer Res

  1. ASARE-WEREHENE M, Communal L, Carmona E, Han Y, et al
    Plasma gelsolin inhibits CD8+ T cell function and regulates glutathione production to confer chemoresistance in ovarian cancer.
    Cancer Res. 2020 Jul 8. pii: 0008-5472.CAN-20-0788.
    PubMed         Abstract available


    Gynecol Oncol

  2. BRIEGER KK, Peterson S, Lee AW, Mukherjee B, et al
    Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32296.
    PubMed         Abstract available

  3. JONES TL, Sandler CX, Spence RR, Hayes SC, et al
    Physical activity and exercise in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32300.
    PubMed         Abstract available


    Int J Cancer

  4. PANOUTSOPOULOU K, Avgeris M, Magkou P, Mavridis K, et al
    miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33182.
    PubMed         Abstract available


    Lancet Oncol

  5. LEDERMANN JA, Oza AM, Lorusso D, Aghajanian C, et al
    Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2020;21:710-722.
    PubMed         Abstract available


    Oncogene

  6. NAIR J, Huang TT, Murai J, Haynes B, et al
    Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
    Oncogene. 2020 Jul 9. pii: 10.1038/s41388-020-1383.
    PubMed         Abstract available


    Oncology (Williston Park)

  7. WRIGHT KM
    Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
    Oncology (Williston Park). 2020;34:175.
    PubMed         Abstract available


    PLoS One

  8. SOLDI R, Ghosh Halder T, Weston A, Thode T, et al
    The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    PLoS One. 2020;15:e0235705.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: